Levofloxacin: penetration into sputum and once-daily treatment of respiratory tract infections.
Nakamori
Y
Y
Department of Respiratory Diseases, Misyuku Hospital, Tokyo, Japan.
Miyashita
Y
Y
Nakatani
I
I
Nakata
K
K
D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D064704:Levofloxacin; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000382:microbiology; D013183:Sputum / Q000378:metabolism*; D016896:Treatment Outcome
D000890:Anti-Infective Agents; D064704:Levofloxacin; D015242:Ofloxacin